Redirecting tumor macrophage activity to fight cancer: Make room for the next era of anti-cancer drugs
- PMID: 34637745
- DOI: 10.1016/j.ccell.2021.09.009
Redirecting tumor macrophage activity to fight cancer: Make room for the next era of anti-cancer drugs
Abstract
Functionally significant proteins expressed by tumor macrophages have emerged as promising anti-cancer targets. In this issue of Cancer Cell, Sun et al. identify two FDA-approved agents that together safely reprogram tumor macrophages into potent anti-tumor effectors, demonstrating the power of engaging both immune system arms to fight cancer.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests Dr. Coussens receives sponsored research support from Syndax Pharmaceuticals Inc., Acerta Pharma, LLC, Prospect Creek Foundation, Lustgarten Foundation for Pancreatic Cancer Research, and Susan G. Komen Foundation. Dr. Coussens serves on advisory boards for Pharmacyclics, Inc., Syndax Pharmaceuticals, Inc., Carisma Therapeutics, Inc., Verseau Therapeutics, Inc., CytomX Therapeutics, Inc., Kineta, Inc., Hibercell, Inc., Cell Signaling Technologies, Alkermes, Inc., Zymeworks, Inc., AstraZeneca Partner of Choice Network, and Genenta Sciences, and is a paid consultant for Cell Signaling Technologies, AbbVie, Inc., and Shasqi, Inc.
Comment on
-
Activating a collaborative innate-adaptive immune response to control metastasis.Cancer Cell. 2021 Oct 11;39(10):1361-1374.e9. doi: 10.1016/j.ccell.2021.08.005. Epub 2021 Sep 2. Cancer Cell. 2021. PMID: 34478639 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
